Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company headquartered in Waltham, Massachusetts, focused on bioprocessing technologies and systems that support the manufacturing of biological drugs. This news page aggregates company announcements, earnings updates, product launches and strategic developments directly related to Repligen’s operations in bioprocessing.
According to its public communications, Repligen serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs), with core focus areas in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. News items often highlight how these focus areas evolve through new products, partnerships and technology integrations.
Investors and industry followers can use this page to review earnings press releases and related Form 8-K announcements, which cover quarterly financial results, guidance updates and commentary on demand trends across Repligen’s franchises and geographies. The company’s releases also discuss the use of non-GAAP financial measures and provide reconciliations to GAAP results.
Repligen’s news flow additionally includes product and technology updates, such as the launch of new chromatography resins in its proteins portfolio and introductions of equipment in areas like mixing and process analytics. Strategic partnerships, including its collaboration with Novasign to integrate machine learning and modeling workflows into Repligen filtration systems, are another recurring theme.
Governance and leadership developments, such as Board chair transitions and senior finance appointments disclosed via press releases and Form 8-K filings, also appear in the news stream. By checking this page regularly, readers can follow how Repligen describes its progress in bioprocessing technology leadership, digitalization initiatives, and its engagement with the biopharmaceutical and CDMO sectors.
Repligen reported first quarter revenue of $151 million, a 16% increase in new modalities revenue, and a 12% increase in Filtration (non-COVID) revenue year-over-year. The company achieved a nine-month book-to-bill ratio of 1.03. Financial performance in Q1 2024 saw a decline in reported revenue and gross profit compared to Q1 2023, primarily due to COVID-related revenue absence and a decline in Proteins revenue. Adjusted figures showed a decrease in income from operations and net income. Cash, cash equivalents, and short-term investments at the end of Q1 2024 were $780.6 million. Repligen reiterated its financial guidance for full year 2024, expecting orders to pick up in the second half of the year. The company's adjusted financial guidance for FY 2024 remains unchanged, with total reported revenue expected to be in the range of $620M - $650M.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.